Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2009

Open Access 01-06-2009 | Meeting abstract

Molecular target therapy – towards curative regimen: a 20-year experience in the treatment of acute promyelocytic leukemia (APL) in the Shanghai Institute of Hematology

Author: Zhi-Xiang Shen

Published in: Journal of Hematology & Oncology | Special Issue 1/2009

Login to get access

Excerpt

Since the first description of acute promyelocytic leukemia (APL) in 1957 as the most malignant form of acute leukemia, several developments have paved the way to make this disease the most curable leukemia in adults and change the paradigm of cancer treatment. Therapy of APL was pioneered by Bernard et al in 1973 demonstrating a striking sensitivity to daunorubicin, probably related to significantly lower P-glycoprotein expression observed in APL cells compared to other subtypes of acute myeloid leukemia (AML). …
Metadata
Title
Molecular target therapy – towards curative regimen: a 20-year experience in the treatment of acute promyelocytic leukemia (APL) in the Shanghai Institute of Hematology
Author
Zhi-Xiang Shen
Publication date
01-06-2009
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue Special Issue 1/2009
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-2-S1-A1

Other articles of this Special Issue 1/2009

Journal of Hematology & Oncology 1/2009 Go to the issue

Meeting abstract

New insights on low-grade and T-cell lymphoma

Meeting report

What's new in the management of chronic lymphocytic leukemia? 2008 ASH Review (New York Medical College, January 31, 2009)

Meeting abstract

Recent progress in the treatment of multiple myeloma: updates and highlights from ASH 2008

Meeting abstract

Update of recent studies in chronic myeloid leukemia

Meeting abstract

Update on chronic immune thrombocytopenic purpura (ITP)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits